Rare Disease Expertise BioPier has a proven track record delivering late-phase studies and rescuing at-risk Phase-3 trials, highlighting opportunities to expand with sponsors seeking risk mitigation and reliable on-time delivery in rare diseases and oncology pipelines.

Submission Readiness Strong focus on (s)NDA/(s)BLA submissions and related activities (ISS, ISE, HTA, eCRT, FDA-IR, Legacy-to-CDISC migrations) suggests cross-selling integrated submission support and regulatory consulting to biotech and pharma clients preparing complex filings.

US-Based Advantage 100% USA-based operations with a senior, experienced biostatistics and programming team positions BioPier as a favorable partner for U.S. sponsors seeking tight communication, compliance, and nearshore agility for high-stakes programs.

Cost and Efficiency Project-based, unit-based model plus referrals and flat reporting structure indicate potential to upsell cost-saving, streamlined CRO services to clients looking to reduce vendor overhead and accelerate study timelines.

Deep Experience Pool A seasoned team with high advanced degrees and long tenure enables capabilities in complex statistical analyses and data management; leverage for high-value collaborations, technology-enabled trials, and expanded services such as data standards migrations and eClinical integrations.